The US FDA has accepted the supplemental biologics license application (sBLA) for trastuzumab deruxtecan (T-DXd; Enhertu) ...

A groundbreaking study reveals the potential of alternative donors in bone marrow transplantation, paving the way for improved patient outcomes and innovative practices.

Harpreet Singh, MD, former director of the FDA's Division of Oncology 2 and chief medical officer of Precision for Medicine, discusses the FDA's draft guidance on the use of overall survival (OS) as ...

Received folinic acid/fluorouracil/oxaliplatin/bevacizumab in first line with initial partial response; progression after 11 ...

Innovative NBTXR3 shows promise in enhancing radiotherapy for recurrent head and neck cancer, potentially transforming ...

The fast track designation is supported by preclinical evidence of antitumor activity by ADCE-D01 in several STS tumor models ...

Preventing relapse of advanced ovarian cancer with PARP inhibitors is now an established strategy. As data from pivotal ...

Prepare for a pivotal shift in the molecular oncology landscape at the 2025 European Society of Medical Oncology (ESMO) Annual Congress, to be held October 17 through 21, in Berlin, Germany.

Patients in the no LND arm had shorter surgery duration, less blood loss, and reduced postoperative hospital stay compared to ...

The FDA has granted fast track designation to the investigational therapeutic agent WTX-124 for the potential treatment of ...

The FDA has approved cemiplimab as an adjuvant treatment for high-risk cutaneous squamous cell carcinoma. The US FDA has ...

The median follow-up of 37 months showed that PSMAiSRT improved FFS and eugonadal FFS, with significant improvements in the ...